<DOC>
	<DOCNO>NCT00522249</DOCNO>
	<brief_summary>The purpose study evaluate combination Pegylated Alfa Interferon ( PEG-Intron ) , Sunitinib Tarceva see drug combination delay disease progression patient metastatic Renal Cell Carcinoma . The first phase study determine best dose Peg-Intron , Sunitinib Tarceva give combination . The safety give drug combination response treatment also examine .</brief_summary>
	<brief_title>Study Pegylated Alfa Interferon , Sunitinib Tarceva Patients With Metastatic RCC</brief_title>
	<detailed_description>Over 75 % RCCs highly vascularize tumor overexpress number growth factor , include VEGF , PDGF , bFGF . In addition , RCC tumor overexpress receptor peptide . These ligand receptor may involve autocrine stimulation tumor cell growth , paracrine stimulation neovascular stromal fibroblast growth support tumor expansion . Novel treatment specifically interrupt signal pathway may significant anti-tumor activity . When take together , data provide rationale investigation combination therapy PEG-Intron , Sunitinib Tarceva clear cell papillary RCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically cytologically confirm metastatic unresectable RCC . Patients must component conventional clear cell renal carcinoma papillary renal carcinoma . No three prior systemic therapy kind RCC include : 1 ) Immunotherapy ( Adjuvant vaccine , Interleukin2 , Interferonα ) 2 ) Chemotherapy 3 ) Molecular target agent ( Nexavar [ Sorafenib ] , Bevacizumab [ Avastin ] ) 4 ) Investigational therapy Patients primary tumor place appropriate surgical candidate strongly encourage ( require ) undergo nephrectomy . Prior palliative radiotherapy metastatic lesion ( ) permit , provide least one measurable and/or evaluable lesion ( ) irradiate . All major surgery type and/or radiotherapy must complete least 4 week prior registration . Patients must recover surgery and/or radiotherapy toxicity prior registration . At time enrollment , patient must evidence metastatic unresectable disease . Paraffin RCC tissue block unstained slide must obtain future chemistry stain every effort make obtain sample . Karnofsky performance status &gt; 70 % . Echocardiogram ejection fraction ≥ 45 % Age &gt; 18 . Must meet required initial laboratory value Patients true chromophobe , oncocytoma , collect duct tumor transitional cell carcinoma NOT eligible . Patients receive small molecule epithelial growth factor inhibitor ( Irresa , Tarceva ) exclude . Patients prior exposure sunitinib exclude . No ongoing hemoptysis , cerebrovascular accident within 12 month , peripheral vascular disease claudication le 1 block , history clinically significant bleeding , potential bleeding and/or clot risk combination therapy . No deep venous thrombosis pulmonary embolus within 12 month randomization ongoing need fulldose oral parenteral anticoagulation . Low dose coumadin ( 1 mg ) maintenance catheter patency daily prophylactic aspirin allow . No evidence current central nervous system ( CNS ) metastasis . Any imaging abnormality indicative CNS metastasis exclude patient study . No significant cardiovascular disease define congestive heart failure ( New York Heart Association Class II , II IV ) angina pectoris require nitrate therapy , recent myocardial infarction ( within last 6 month ) . No active ischemia electrocardiogram . No patient uncontrolled hypertension ( define blood pressure &gt; 160 mmHg systolic and/or &gt; 90 mmHg diastolic medication ) . Any ongoing requirement systemic corticosteroid therapy ( except replacement therapy adrenal insufficiency ) permit . Topical and/or inhale steroid allow . Patients preexist thyroid abnormality whose thyroid function maintain normal range medication ineligible . No uncontrolled psychiatric disorder . Patients delay heal wound , ulcer , and/or bone fracture eligible . Patients 'currently active ' second malignancy nonmelanoma skin cancer eligible . Pregnant woman exclude ( negative urine serum pregnancy test require ) potential teratogenic abortifacient effect therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>M3thodist</keyword>
	<keyword>Pegylated Alfa Interferon</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Peg IFN</keyword>
</DOC>